Citation

  • Authors: Rasoulouniriana D. et al.
  • Year: 2019
  • Journal: J Clin Invest 129 4151-4164
  • Applications: in vitro / DNA / jetPRIME
  • Cell types:
    1. Name: GP+E-86
    2. Name: HEK-293FT

Abstract

While a high frequency of Th1 cells in tumors is associated with improved cancer prognosis, this benefit has been attributed mainly to support of cytotoxic activity of CD8+ T cells. By attempting to potentiate antibody-driven immunity, we found a remarkable synergy between CD4+ T cells and tumor-binding antibodies. This surprising synergy was mediated by a small subset of tumor-infiltrating CD4+ T cells that express the high-affinity Fc

Go to